Key Takeaways
- • Warhound emerged from stealth on October 22 with $200 million in seed funding at a $1.2 billion post-money valuation, according to TechCrunch.
- • The startup, co-founded by Colossal Biosciences founder Ben Lamm and Anduril founder Palmer Luckey with David Spirk as CEO, aims to develop genetically enhanced dogs for military and emergency work.
- • Official announcement names ARK Invest and Franklin Templeton among backers; Sequoia Capital is the main investor per S&P Capital IQ, with In-Q-Tel, 8VC and Corner Ventures also named, but individual amounts are undisclosed.
- • No dogs have been born yet; first births are expected in early 2027 and the company hopes to have dogs in service within two years, with no deployed product or announced government orders.
- • Warhound targets a supply gap: more than 80% of U.S. military working dogs come from Europe, and fewer than half of those after a roughly three-year acquisition and training process are fit for service.
Summary
Warhound emerged from stealth on October 22 with $200 million in seed funding and a $1.2 billion post-money valuation, TechCrunch reported. The company plans to develop genetically enhanced dogs for military and emergency work. Its official announcement names ARK Invest and Franklin Templeton among its backers.
The venture is the brainchild of Colossal Biosciences founder Ben Lamm and Anduril founder Palmer Luckey, and David Spirk leads the company as CEO. Colossal plans to collect cells from high-performing Belgian Malinois and German Shepherds, edit their genes to improve health and performance, and use subsidiary Viagen for cloning. Anduril plans to equip the dogs with protective equipment, sensors and software that let handlers monitor conditions on the ground. TechCrunch reports that Luckey holds no ownership stake in Warhound, while Colossal holds shares and licenses its technology to the firm. The dogs would be used to detect explosives, assist in searches and handle dangerous assignments. None has been born yet; the first births are expected in early 2027.
Among the backers are Sequoia Capital, In-Q-Tel, 8VC, ARK Invest and Franklin Templeton, with TechCrunch also citing Corner Ventures as a participant. S&P Capital IQ identifies Sequoia as the main investor. The individual contribution amounts and the specific ARK and Franklin funds involved have not been disclosed. A separate Form D filed October 21 for Animal Capital Warhound SPV I reports $9.62 million raised from 23 investors, with a first sale date of September 23, but it names no investors and does not establish its relationship to the $200 million round.
Warhound cites a supply problem as its rationale: more than 80% of U.S. military working dogs come from Europe, and after a roughly three-year acquisition and training process, fewer than half are considered fit for service. The company says it is working with the American Humane Society on training certification. SIPRI estimates global military expenditure reached $2.887 trillion in 2025, up 2.9%, with Europe's spending up 14% and U.S. military budget down 7.5%. PitchBook's Q2 report describes a defense-tech market increasingly split between established companies and early-stage bets, and Warhound falls into the latter category.
Warhound has no deployed product or announced government orders. It must prove its cloning and gene-editing methods, protect animal welfare and secure government approvals. Franklin Templeton created Franklin Crypto after acquiring 250 Digital in June, and ARK tokenized its venture fund on Ethereum in September, but neither development establishes how Warhound was financed.
The venture is the brainchild of Colossal Biosciences founder Ben Lamm and Anduril founder Palmer Luckey, and David Spirk leads the company as CEO. Colossal plans to collect cells from high-performing Belgian Malinois and German Shepherds, edit their genes to improve health and performance, and use subsidiary Viagen for cloning. Anduril plans to equip the dogs with protective equipment, sensors and software that let handlers monitor conditions on the ground. TechCrunch reports that Luckey holds no ownership stake in Warhound, while Colossal holds shares and licenses its technology to the firm. The dogs would be used to detect explosives, assist in searches and handle dangerous assignments. None has been born yet; the first births are expected in early 2027.
Among the backers are Sequoia Capital, In-Q-Tel, 8VC, ARK Invest and Franklin Templeton, with TechCrunch also citing Corner Ventures as a participant. S&P Capital IQ identifies Sequoia as the main investor. The individual contribution amounts and the specific ARK and Franklin funds involved have not been disclosed. A separate Form D filed October 21 for Animal Capital Warhound SPV I reports $9.62 million raised from 23 investors, with a first sale date of September 23, but it names no investors and does not establish its relationship to the $200 million round.
Warhound cites a supply problem as its rationale: more than 80% of U.S. military working dogs come from Europe, and after a roughly three-year acquisition and training process, fewer than half are considered fit for service. The company says it is working with the American Humane Society on training certification. SIPRI estimates global military expenditure reached $2.887 trillion in 2025, up 2.9%, with Europe's spending up 14% and U.S. military budget down 7.5%. PitchBook's Q2 report describes a defense-tech market increasingly split between established companies and early-stage bets, and Warhound falls into the latter category.
Warhound has no deployed product or announced government orders. It must prove its cloning and gene-editing methods, protect animal welfare and secure government approvals. Franklin Templeton created Franklin Crypto after acquiring 250 Digital in June, and ARK tokenized its venture fund on Ethereum in September, but neither development establishes how Warhound was financed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.